A review of the clinical efficacy and safety of the adjuvant therapy in renal cell carcinoma: the evidence base for the health technology assessment in Ukraine
Social Pharmacy in Health Care · 03.07.2026 · 12 (2) · 3-14
DOI: 10.24959/sphhcj.26.387 ↗Kurz gefasst
Fachartikel in der Zeitschrift Social Pharmacy in Health Care, online erschienen am 03.07.2026. Verfasst von A. V. Volkova und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Renal cell carcinoma (RCC) remains one of the most common malignant kidney tumors, in which even after radical nephrectomy, patients with intermediate-high and high risk have a significant probability of recurrence. Accordingly, the search for effective adjuvant treatment modalities is a clinically and pharmacoeconomically important task, especially in the context of the health technology assessment and decision-making on public funding.
Aim
To conduct an analytical review of randomized controlled trials and high-quality reviews evaluating adjuvant systemic treatment modalities for RCC for the purpose of the subsequent health technology assessment. Materials and methods. The study materials were publications selected after screening according to eligibility criteria related to the population, design, intervention, and clinical outcomes. Forty (40) studies were included in the qualitative synthesis. The primary endpoint of the clinical efficacy in most studies was recurrence-free survival (RFS) at a median follow-up of 24 to 76 months across different trials. The clinical efficacy assessment was based on published hazard ratios (HR) and the frequency of grade 3–4 adverse events. The study used standardized data collection, the content analysis, the narrative synthesis of results, and generalization. Results and discussion. Pembrolizumab was found to provide the greatest benefit in reducing the risk of recurrence (RFS HR 0.63–0.72) and was associated with favorable overall survival (OS) signals (HR 0.52–0.62). Sunitinib demonstrated RFS HRs of 0.76–0.94; other interventions generally had HRs close to or above 0.85. Immuno-oncology agents had a lower frequency of grade 3–4 toxicity (≈9%–32%) compared to tyrosine kinase inhibitors/mTOR inhibitors (≈23%–72%). A statistically significant effect on OS was identified only for pembrolizumab (HR 0.52–0.62; p < 0.05 at three follow-up time points). For sunitinib, nivolumab, atezolizumab, everolimus, and other agents, no statistically significant differences in OS were observed.
Conclusions
The results of the analytical review indicate that pembrolizumab and sunitinib are consistent candidates for the adjuvant therapy of RCC, while the benefit of targeted agents appears to be more selective for high-risk subgroups. In accordance with the aim of the study, the results obtained can be used as an evidence base for further health technology assessment and developing recommendations on public funding of medicines for the adjuvant treatment of RCC.
Zitieren
APA
Volkova, A. V., & Kaiota, O. V. (2026). A review of the clinical efficacy and safety of the adjuvant therapy in renal cell carcinoma: the evidence base for the health technology assessment in Ukraine. Social Pharmacy in Health Care, 12(2), 3-14. https://doi.org/10.24959/sphhcj.26.387
Vancouver
Volkova AV, Kaiota OV. A review of the clinical efficacy and safety of the adjuvant therapy in renal cell carcinoma: the evidence base for the health technology assessment in Ukraine. Social Pharmacy in Health Care. 2026;12(2):3-14. doi:10.24959/sphhcj.26.387
BibTeX
@article{Volkova2026,
author = {Volkova, A. V. and Kaiota, O. V.},
title = {A review of the clinical efficacy and safety of the adjuvant therapy in renal cell carcinoma: the evidence base for the health technology assessment in Ukraine},
journal = {Social Pharmacy in Health Care},
year = {2026},
volume = {12},
number = {2},
pages = {3--14},
doi = {10.24959/sphhcj.26.387}
}
EUVIMED